Technical Analysis for CLBS - Caladrius Biosciences, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| See historical CLBS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 19 | Bollinger Band Squeeze | Range Contraction | 0.00% |
| Mar 19 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Mar 19 | BB Squeeze + Lower Band Touch | Range Contraction | 0.00% |
| Mar 19 | Inside Day | Range Contraction | 0.00% |
| Mar 19 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Mar 18 | Bollinger Band Squeeze | Range Contraction | 3.20% |
| Mar 18 | BB Squeeze + Lower Band Touch | Range Contraction | 3.20% |
| Mar 18 | Lower Bollinger Band Touch | Weakness | 3.20% |
| Mar 15 | Bearish Engulfing | Bearish | -1.28% |
| Mar 15 | Fell Below 20 DMA | Bearish | -1.28% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-14
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, develops cell based therapeutics in the United States. It is developing NBS20, a targeted cancer immunotherapy product that is in Phase III clinical trials for the treatment of metastatic melanoma; NBS10, a ischemic repair product that is in Phase II clinical trial to preserve heart muscle function following an acute myocardial infarction; and NBS03D, an immune modulation product that is in Phase II clinical trials for the treatment of type 1 diabetes. The company, through its subsidiary, Progenitor Cell Therapy, offers process development and clinical manufacturing services. It is also involved in oncology, cord blood, and adult stem cell processing and banking activities; and the provision of clinical services. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was founded in 1980 and is headquartered in New York, New York.
Banking Biopharmaceutical Cancer Diabetes Immunotherapy Cancer Immunotherapy Metastatic Melanoma Clinical Services Acute Myocardial Infarction Treatment Of Metastatic Melanoma
Banking Biopharmaceutical Cancer Diabetes Immunotherapy Cancer Immunotherapy Metastatic Melanoma Clinical Services Acute Myocardial Infarction Treatment Of Metastatic Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CLBS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 11.65 |
| 52 Week Low | 3.05 |
| Average Volume | 29,354 |
| 200-Day Moving Average | 4.9206 |
| 50-Day Moving Average | 4.5153 |
| 20-Day Moving Average | 3.9868 |
| 10-Day Moving Average | 3.8725 |
| Average True Range | 0.2395 |
| ADX | 24.95 |
| +DI | 19.6908 |
| -DI | 31.6253 |
| Chandelier Exit (Long, 3 ATRs ) | 3.6415 |
| Chandelier Exit (Short, 3 ATRs ) | 4.3285 |
| Upper Bollinger Band | 4.3022 |
| Lower Bollinger Band | 3.6714 |
| Percent B (%b) | 0.31 |
| BandWidth | 15.822213 |
| MACD Line | -0.1822 |
| MACD Signal Line | -0.198 |
| MACD Histogram | 0.0158 |
| Fundamentals | Value |
|---|---|
| Market Cap | 36.48 Million |
| Num Shares | 9.43 Million |
| EPS | -11.27 |
| Price-to-Earnings (P/E) Ratio | -0.34 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | -0.03 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.24 | ||||
| Resistance 3 (R3) | 4.20 | 4.04 | 4.18 | ||
| Resistance 2 (R2) | 4.04 | 3.95 | 4.06 | 4.16 | |
| Resistance 1 (R1) | 3.96 | 3.89 | 4.00 | 3.99 | 4.14 |
| Pivot Point | 3.79 | 3.79 | 3.82 | 3.81 | 3.79 |
| Support 1 (S1) | 3.71 | 3.70 | 3.75 | 3.75 | 3.60 |
| Support 2 (S2) | 3.55 | 3.64 | 3.56 | 3.58 | |
| Support 3 (S3) | 3.46 | 3.55 | 3.56 | ||
| Support 4 (S4) | 3.50 |
